You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 3900 results
  1. Minimally Invasive On Demand Electrical Nerve Block (OD-ENB) Device for Peripheral Pain

    SBC: H-CUBED            Topic: NIDA

    Knee  Osteoarthritis  (KOA)  is  a  degenerative  joint  disease  that  leads  to  significant  pain  and  functional  disability  affecting  over  30%  of  older  adults  making  it  one  of  the  most  common  and  debilitating  conditions  related  to  aging.  This  disease  results  in  a  loss  of  mobility,  reduced  quality  of  life,  and  in ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Physics-informed Machine Learning approach for a selective, sensitive, and rapid sensor for detecting unsafe levels of carcinogenic/toxic VOCs

    SBC: Prometheus Technologies, LLC            Topic: NIEHS

    Project Summary Each year, between 340,000 and 900,000 premature deaths can be linked to air pollution caused by releasing Volatile Organic Compounds (VOCs), i.e., an estimated 1.8 billion tons of VOCs are emitted to the global environment each year. Also, some VOCs cause serious adverse health effects even at the trace level concentration, e.g., cancer, damage to the central nervous and immune sy ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Vitiligo topical treatment applying a potent, highly selective MC1R agonist

    SBC: MC1R VENTURES LLC            Topic: NIAMS

    PROJECT SUMMARY Vitiligo is the most common acquired hypopigmentary disorder that afflicts 0.5-2% of the world population, from all ethnicities and skin color. It is characterized by loss of melanocytes, which is often progressive, resulting in depigmented skin lesions. Vitiligo can be segmental (5-16% of all cases) or most commonly, non-segmental. It is a disease of young adults, as 25% of all no ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability

    SBC: BIOCHIP LABS, INC.            Topic: NHLBI

    PROJECT SUMMARY Deformability and non-adherence are the most intrinsic biorheological properties of red blood cells (RBCs), as they play a critical role in modulating RBC perfusion through the microvasculature. In acquired or inherited blood disorders, such as sickle cell disease (SCD), these two interrelated properties are pathologically altered. SCD is an autosomal recessive disorder associated ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Adipose Targeted Gene Therapy for Lipodystrophy

    SBC: ZVELT THERAPEUTICS INC.            Topic: NIDDK

    PROJECT SUMMARY Lipodystrophy includes a heterogeneous group of disorders that are characterized by abnormal or degenerative conditions of the adipose tissue. This rare and often underdiagnosed condition can be partial/localized or generalized and is generally associated with metabolic disorders such as insulin resistance, diabetes, hyperglycemia, hyperlipidemia, and other severe conditions. Lipod ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. High-throughput functional analysis and clinical relevance of all possible variants of a gene

    SBC: HELIGENICS, INC.            Topic: NHGRI

    Modern pharmaceuticals have greatly improved the quality of life for many patients suffering a variety of illnesses. Unfortunately, among the 17 most commonly prescribed drugs, only 6 are highly effective for most patients, 5 have a modest effect, and 6 show little clinical effect. Worse still, unwanted illness and death from treatment of patients with the incorrect drug or dosage causes over 275, ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities

    SBC: EPIVAX, INC.            Topic: NIAID

    ABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and processing of biologics, the presence of immunogenic PRPI continue to raise concerns about drug safety and efficacy. We propose an innovative approach for assessing immunogenicity risk of PRPI using o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia

    SBC: Haima Therapeutics LLC            Topic: NHLBI

    Project Summary/Abstract The normal platelet count in human blood is 150,000-400,000/μL, and these platelets are responsible for efficient hemostatic surveillance and bleeding mitigation in the body. Thrombocytopenia (TCP, low platelet count) is a condition caused by a decrease in platelet production, increase in platelet destruction or consumption, or increase in splenic sequestration. The age-a ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Ceragenin-coated pedicle screws to tackle surgical-site infections.

    SBC: N8 MEDICAL INC            Topic: NIAID

    PROJECT SUMMARY Surgical Site Infection (SSI) is one of the major complications of implant surgery, especially in spinal surgery, where SSI leads to unfavorable health and functional outcomes. Antimicrobial coatings have been explored as a way to prevent microbial colonization on the surface of pedicle screws. However, current strategies to generate antimicrobial coatings do not show broad-spectru ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes

    SBC: IRXREMINDER LLC            Topic: 104

    Abstract - Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes Tardive dyskinesia (TDD) is a common debilitating side effect of antipsychotic use. Characterized most notably by involuntary facial movements such as grimacing, involuntary lip, mouth, and tongue movements, and eye blinking, TDD is difficult to treat and potentially irreversible. Psychiatrists and othe ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government